J.P. Morgan Healthcare

With a transformative merger and volatile markets as the backdrop, Devon CEO Clay Gaspar faces a critical moment. Here's the why behind the buy for investors.

Enveric Biosciences heads to a key UBS investor day to pitch its non-hallucinogenic antidepressant, EB-003. Can it secure the capital needed to revolutionize CNS?

As Royalty Pharma prepares for a key investor conference, we explore the powerful, low-profile business model that funds blockbuster drugs and shapes innovation.

As Alkermes prepares for a key investor conference, it's not just about numbers. It's about a bold new strategy in sleep medicine, a billion-dollar pipeline, and a new CEO.

A new study reveals patients trust AI algorithms over doctor recommendations, forcing a high-stakes reckoning for medical practices and patient safety alike.

As Prime Medicine prepares for a key investor conference, its next-gen 'search and replace' gene editing technology faces a crucial test. Can it deliver on its promise?

As its CEO heads to a top investor conference, Zealand Pharma leverages AI and novel peptides to challenge giants in the multi-billion-dollar obesity market.

Groundbreaking research on new drug classes, the gut-brain axis, and personalized medicine will be unveiled at the upcoming American Headache Society meeting.

MBX Biosciences prepares for the Jefferies conference, with investors eyeing updates on its late-stage hypoparathyroidism drug and promising obesity portfolio.

A novel device that treats hypertension from outside the artery shows early promise, challenging market leaders and offering new hope for millions.

Unifi launches Luxel, a new yarn blending linen's feel with performance tech and circular recycling, aiming to redefine sustainable fashion and home goods.

With its lead CAR-T therapy, Descartes-08, in late-stage trials, Cartesian Therapeutics is set to update investors on its pioneering work in autoimmune disease.

Cloud security leader Zscaler prepares for high-stakes investor conferences, aiming to showcase its financial strength and AI-driven growth strategy.

With booming exports and robust government backing, Italy is making a strategic play to become a global life sciences powerhouse. Here's what's driving the momentum.

At a major San Francisco summit, Chinese biotechs unveiled breakthrough heart and cancer drugs, signaling a strategic shift from manufacturing to global innovation.

Vericel posts strong 2025 results driven by its MACI cartilage therapy. The biotech leader is now investing in a new facility and a clinical trial for ankle repair.

With its first MASH drug a success, Madrigal aims to redefine treatment by combining it with a newly licensed Pfizer asset. Is this the future?

Oculis is advancing a neuroprotective drug for optic neuropathies and a first-of-its-kind eye drop for diabetic macular edema, aiming at $10B+ markets.

Azafaros presents its promising drug, nizubaglustat, for untreatable rare neurological disorders, backed by major funding and late-stage clinical trials.

Newcomer Candid Therapeutics is set to unveil its T-cell engager platform at J.P. Morgan, a move that could shake up the autoimmune treatment landscape.